Follow up after a family based genetic screening programme for familial hypercholesterolaemia: is screening alone enough?
van Maarle, M.C.; Stouthard, M.E.A.; Marang-van de Mheen, P.J.; Klazinga, N.S.; Bonsel, G.J.

Published in:
BMJ : British medical journal

DOI:
10.1136/bmj.324.7350.1367

Citation for published version (APA):
van Maarle, M. C., Stouthard, M. E. A., Marang-van de Mheen, P. J., Klazinga, N. S., & Bonsel, G. J. (2002). Follow up after a family based genetic screening programme for familial hypercholesterolaemia: is screening alone enough? BMJ : British medical journal, 324, 1367-1368. DOI: 10.1136/bmj.324.7350.1367
Follow up after a family based genetic screening programme for familial hypercholesterolaemia: is screening alone enough?

Merel C van Maarel, Marlies E A Stouthard, Perla J Marang-van de Mheen, Niek S Klazinga and Gouke J Bonsel

BMJ 2002;324;1367-1368
doi:10.1136/bmj.324.7350.1367

Updated information and services can be found at: http://bmj.com/cgi/content/full/324/7350/1367

These include:

References
This article cites 3 articles, 1 of which can be accessed free at: http://bmj.com/cgi/content/full/324/7350/1367#BIBL
1 online articles that cite this article can be accessed at: http://bmj.com/cgi/content/full/324/7350/1367#otherarticles

Rapid responses
One rapid response has been posted to this article, which you can access for free at: http://bmj.com/cgi/content/full/324/7350/1367#responses
You can respond to this article at: http://bmj.com/cgi/eletter-submit/324/7350/1367

Email alerting service
Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article

Topic collections
Articles on similar topics can be found in the following collections
- Other Cardiovascular Medicine (2025 articles)
- Other Endocrinology (613 articles)
- Other nutrition and metabolism (1245 articles)
- Screening (711 articles)

Notes
HSV-1 was found in 751 (70%) of all positive swabs in women <25 years, 141 (41%) in men <25 years, 413 (49%) in women ≥25 years, and 182 (25%) in men ≥25 years. In 1986-8, 33% (187) of all positive swabs were due to HSV-1, rising progressively to 56% (548) in 1998-2000 (P < 0.0001). A significant rise (P < 0.0001, 1986 v 2000) in the proportion of isolates attributable to HSV-1 occurred in each of the four age and sex subgroups (P < 0.0001) (figure).

Comment

Both the number and percentage of genital HSV-1 infections have risen. Genital infection with HSV-1 is strongly associated with being young (aged <25 years) and being female.

Explanations include changing host susceptibility and changing sexual behaviour of the population. The population seroprevalence of HSV-1 is falling; increasing numbers of young adults are susceptible to HSV-1 infection. As genital tract reactivation of latent HSV-1 infection is infrequent, most new cases of genital HSV-1 infection are likely to be due to orogenital transmission, but there is no evidence suggesting that oral sex practices have changed substantially. The occurrence of HSV-1 infection in women, seen consistently in other studies, is unexplained.

These results have three important implications for management. Firstly, patients should be counselled about the more favourable clinical course of genital HSV-1 than of HSV-2 infection; recurrences are generally milder and infrequent. Secondly, subclinical shedding of HSV-1 is less common; this has a direct bearing on the likelihood of transmission. Thirdly, preventive strategies for genital herpes should focus on the risk of unprotected orogenital intercourse, which is frequently perceived as “safe” in the context of sexually transmitted infections.

We thank Geoffrey Clements, previously director of the West of Scotland Specialist Virology Centre.

Contributors: AS initiated and designed the study, analysed and interpreted the results, and wrote the paper. JN and NM analysed and interpreted the results and wrote the paper. GG contributed to the study design and analysis of results. WC contributed to the study design, analysis, and interpretation of the results. AS is guarantor.

Funding: No additional funding.

Competing interests: None declared.

(Accepted 3 December 2001)

Follow up after a family based genetic screening programme for familial hypercholesterolaemia: is screening alone enough?

Merel C van Maarle, Marlies E A Stouthard, Perla J Marang-van de Mheen, Niek S Klazinga, Gouke J Bonsel

Familial hypercholesterolaemia is an autosomal dominant disorder of lipoprotein metabolism, with an estimated frequency of 1 in 500 in Western countries; it results in excess mortality from coronary artery disease. Now that the genetic defects can be detected and statins are available to lower lipids effectively, genetic screening has been considered. In 1994 a family based genetic screening programme for familial hypercholesterolaemia started in the Netherlands. The programme's effectiveness rests on the evidence based treatment of newly identified patients. We therefore assessed the subsequent preventive care and short term clinical outcome in people testing positive for familial hypercholesterolaemia as a proxy for the expected long term level of coronary artery disease.

Participants, methods, and results

The foundation for tracing hereditary hypercholesterolaemia performs cascade screening in families of patients with clinically diagnosed familial hypercholesterolaemia with a known mutation, actively approaching first degree and second degree relatives. Family members are tested for the known mutation; their cholesterol level is not measured. The test result is communicated only to the person screened (by mail). The foundation is not involved in subsequent treatment or in monitoring follow up.

We conducted the evaluation study from March to September 1998 in all 215 people who tested positive from a consecutive cohort of 677 people screened as part of the programme. The inclusion criteria were consent to genetic testing and the current study, a positive test result, and age 18 or over.

We collected data with three self administered questionnaires—at screening and at 7 months and 18 months after communication of the test result. The main outcome measures were quality of treatment according to the key recommendations of the Dutch guidelines on hypercholesterolaemia and quality of clinical outcome by achieved cholesterol level, body mass index, and smoking status (table).
Quality of treatment and clinical outcome in people testing positive for familial hypercholesterolaemia. Values are numbers (percentages)

<table>
<thead>
<tr>
<th>Follow up</th>
<th>Newly identified cases (n=41)</th>
<th>Confirmed cases (n=125)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>At screening</td>
<td>At follow up (34 (83))</td>
</tr>
<tr>
<td>Cholesterol checked</td>
<td>17 (41)*</td>
<td>29 (71)</td>
</tr>
<tr>
<td>Use of drugs</td>
<td>0*</td>
<td>14 (34)</td>
</tr>
<tr>
<td>Use of statin</td>
<td>0*</td>
<td>14 (34)</td>
</tr>
<tr>
<td>Diet</td>
<td>3 (12)*</td>
<td>19 (46)</td>
</tr>
<tr>
<td>Lifestyle advice</td>
<td>0*</td>
<td>34 (83)</td>
</tr>
<tr>
<td>Quality of treatment:†</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Good</td>
<td>10 (24)</td>
<td>20 (48)</td>
</tr>
<tr>
<td>Moderate</td>
<td>0</td>
<td>4 (10)</td>
</tr>
<tr>
<td>Unsatisfactory</td>
<td>31 (76)</td>
<td>16 (39)</td>
</tr>
<tr>
<td>Missing</td>
<td>0</td>
<td>1 (2)</td>
</tr>
<tr>
<td>Known hypercholesterolaemia</td>
<td>9(22)*</td>
<td>14 (34)</td>
</tr>
<tr>
<td>Cholesterol unknown</td>
<td>31 (76)*</td>
<td>9 (22)*</td>
</tr>
<tr>
<td>Smoking</td>
<td>14 (34)</td>
<td>12 (29)</td>
</tr>
<tr>
<td>Body mass index &gt;27 kg/m²</td>
<td>3 (7)</td>
<td>4 (10)</td>
</tr>
<tr>
<td>Quality of clinical outcome:‡</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Good</td>
<td>5 (12)</td>
<td>15 (37)</td>
</tr>
<tr>
<td>Moderate</td>
<td>5 (12)</td>
<td>6 (15)</td>
</tr>
<tr>
<td>Unsatisfactory</td>
<td>31 (76)</td>
<td>19 (46)</td>
</tr>
<tr>
<td>Missing</td>
<td>0</td>
<td>1 (2)</td>
</tr>
</tbody>
</table>

NR—not relevant.
*Significant difference in time (P<0.05).
†Good-use of statin (depending on cholesterol level), adherence to diet, and advice to quit smoking and lose weight if necessary; moderate-use of statin, without diet or appropriate lifestyle advice; unsatisfactory—no drugs while hypercholesterolaemic, or using cholesterol lowering drugs other than statins.
‡Good—cholesterol <6.5 mmol/l; body mass index <27 kg/m², and non-smoker; moderate—cholesterol <6.5 mmol/l and body mass index >27 kg/m², smoker, or both; unsatisfactory—cholesterol >6.5 mmol/l or unknown, regardless of body mass index or smoking status.

We divided the people testing positive into two categories: those with an unknown cholesterol concentration or with normal cholesterol without treatment at the time of screening ("newly identified cases") and those known to have hypercholesterolaemia (cholesterol ≥6.5 mmol/l) or being treated for this condition ("confirmed cases").

One hundred and sixty six (77%) participants filled out all three questionnaires. Respondents and people lost to follow up differed in only one characteristic—use of statin (57% v 39%, P < 0.05).

Seventy three (44%) respondents were men, 41 (25%) were newly identified, and 125 (75%) were confirmed cases. The confirmed cases were older (48.2 v 38.9 years), had higher cholesterol concentrations (10.7 v 6.0 mmol/l), if known, and were more likely to have at least one first degree relative with cardiovascular disease (62 (50%) v 13 (32%)) or one premature cardiovascular death in the family (26 (21%) v 2 (5%)) (P < 0.05 for all comparisons).

Although the quality of treatment and clinical outcome improved substantially over time in both groups (table), people testing positive for familial hypercholesterolaemia did not attain an optimal level of care. Quality of treatment was still unsatisfactory in 33 (20%) cases, and quality of clinical outcome was still insufficient in 75 (45%). Fifty eight (35%) participants were hypercholesterolaemic at follow up, nine (16%) of those with hypercholesterolaemia did not take statins, and 40 (24%) participants smoked.

Comment

Both confirmed and newly identified patients benefit from screening for familial hypercholesterolaemia, as their risk status improves and cholesterol lowering treatment is instituted, but in almost half of all cases the achieved level of care does not keep up with current guidelines. Opportunities for improvement towards current guidelines include physician education, better implementation of guidelines, and, especially, an intensification of the link between diagnosis and follow up care in the screening process.

We thank the respondents for their enthusiasm and Marinum-Umans-Eckenhausen and the genetic field workers of the foundation for tracing hereditary hypercholesterolaemia for their support and help with inclusion of the study population.

Contributors: All authors conceived the study, and MCvM and MEAS collected the data. MCvM, MEAS, and JGB contributed to the analysis and interpretation of the data, and all authors contributed to the preparation of the paper. MCvM is the guarantor.

Funding: Health Research and Development Council of the Netherlands (grant number 28-2751).

Competing interests: None declared.